This announcement signals clear leadership from the UK and Switzerland on the importance of a strong intellectual property (IP) framework to support life sciences innovation and contains truly world-leading IP provisions. The agreement sends a clear signal to global companies that both regions are committed to supporting and attracting pharmaceutical investment. We hope this deal can serve as a blueprint for future FTAs between the EU and its trading partners.